L.A.S. Romeiro et al. / European Journal of Medicinal Chemistry 46 (2011) 3000e3012
3011
[9] J.R. Docherty, Subtypes of functional a1-adrenoceptor, Cell. Mol. Life Sci.
67 (2010) 405e417.
[10] W.H. Frishman, F. Kotob, Alpha-adrenergic blocking drugs in clinical medi-
cine, J. Clin. Pharmacol. 39 (1999) 7e16.
[11] A. Leonardi, G. Motta, C. Riva, L. Guarneri, E. Poggesi, 1,4-disubstituted
piperazines, U.S. Patent (2001) 6,271,234.
[12] B. Kenny, S. Ballard, J. Blagg, D.J. Fox, Pharmacological options in the treatment
of benign prostatic hyperplasia, J. Med. Chem. 40 (1997) 1293e1315.
[13] Y. Kojima, S. Sasaki, N. Oda, T. Koshimizu, Y. Hayashi, M. Kiniwa, G. Tsujimoto,
K. Kohri, Prostate growth inhibition by subtype-selective alpha(1)-adreno-
ceptor antagonist naftopidil in benign prostatic hyperplasia, Prostate 69
(2009) 1521e1528.
[36] E.F. Silva, E.J. Barreiro, The synthesis and antiinflammatory activity of 1-alkyl-
isochroman-1-yl acetic acids derivatives, J. Braz. Chem. Soc. 4 (1993) 40e44.
[37] P.L. Compagno, M. Miocque, Addition of nucleophilic reagent on nitrile triple
bond. 2. Addition of alcohols, of nitrogen compounds of organometallics e
condensation of nitrile molecules, Ann. Chim. France 5 (1970) 23e37.
[38] B. Decroix, J. Morel, P.J. Pastour, Reactions of alcohols in the presence of
hydrogen-chloride with dicyano-thiophens and dicyano-selenophens and
with cyano(formyl)-thiophens, Chem. Res. (S) (1978) 134e135.
[39] S.R. Varma, R. Dahiya, S. Kumar, Clay catalyzed synthesis of imines and
enamines under solvent-free conditions using microwave irradiation, Tetra-
hedron Lett. 38 (1997) 2039e2042.
[40] M. Satoh, K. Enomoto, I. Takayanagi, K. Koike, Analysis of a1-adrenoceptor
subtypes in rabbit aorta and arteries: regional difference and co-existence,
Eur. J. Pharmacol. 374 (1999) 229e240.
[14] R.R. Ruffolo Jr., J.P. Hieble, Adrenoceptor pharmacology: urogenital applica-
tions, Eur. Urol. 36 (1999) 17e22.
[15] H. Lepor, S. Auerbach, B.A. Puras, P. Narayan, M. Soloway, F. Lowe, T. Moon,
G. Leifer, P. Madsen, Randomized placebo-controlled multicenter study of the
efficacy and safety of terazosin in the treatment of benign prostatic hyper-
plasia, J. Urol. 148 (1992) 1467e1474.
[41] R.R. Neubig, M. Spedding, T. Kenakin, A. Christopoulos, International union of
pharmacology committee on receptor nomenclature and drug classification.
XXXVIII. Update on terms and symbols in quantitative pharmacology, Phar-
macol. Rev. 55 (2003) 597e606.
[16] H. Lepor, R. Tang, S. Meretyk, E. Shapiro, Binding and functional properties of
alpha1 adrenoceptors in different regions of the human prostate, J. Urol. 150
(1993) 252e256.
[42] H. Piao, T. Taniguchi, S. Nakamura, J. Zhu, F. Suzuki, D. Mikami, I. Muramatsu,
Cloning of rabbit a1b-adrenoceptor and pharmacological comparison of a1a-,
a1b- and a1d-adrenoceptors in rabbit, Eur. J. Pharmacol. 396 (2000) 9e17.
[43] D.L. Bautista, D.H. Morris, L. Stein, W. Asher, T. Hammitt, A two model receptor
system of the alpha1D adrenergic receptor to describe interactions with
epinephrine and BMY 7378, J. Chem. Inf. Model. 46 (2006) 334e344.
[44] M.-M. Zhao, J. Hwa, D.M. Perez, Identification of critical extracellular loop
residues involved in a1-adrenergic receptor subtype-selective antagonist
binding, Mol. Pharmacol. 50 (1996) 1118e1126.
[45] Y. Nagaoka, M. Ahmed, M. Hossain, M.A. Bhuiyan, M. Ishiguro, T. Nakamura,
M. Watanabe, T. Nagatomo, Amino acids of the human a1d-adrenergic
receptor involved in antagonist binding, J. Pharmacol. Sci. 106 (2008)
114e120.
[17] S. Tatemichi, K. Kobayashi, A. Maezawa, M. Kobayashi, Y. Yamazaki, N. Shibata,
a
1-Adrenoceptor subtype selectivity and organ specificity of silodosin
(KMD-3213), Yakugaku Zasshi 126 (2006) 209e216.
[18] D.R. Blue, A.P.D.W. Ford, D.J. Morgans, T.J. Williams, Q.-M. Zhu, The conscious
’reflex-compromised’ rat: a model for evaluating the hypotensive potencies of
the alpha(1)-adrenoceptor antagonists prazosin, tamsulosin and Ro 70e0004,
Br. J. Pharmacol. 120 (1997) 107P.
[19] M.C. Beduschi, R. Beduschi, J. Oesterling, Alpha-blockade therapy for benign
prostatic hyperplasia: from
adrenergic antagonist, Urology 51 (1998) 861e872.
[20] B. Malloy, D. Price, R. Price, A. Bienstock, M. Dole, B. Funk, C. Donatucci,
D. Schwinn, 1-Adrenergic receptor subtypes in human detrusor, J. Urol. 160
a nonselective to a more selective alpha1A-
[46] M.L. López-Rodríguez, M. Morcillo, T.K. Rovat, E. Fernández, B. Vicente,
A.M. Sanz, M. Hernández, L. Orensanz, Synthesis and structure-activity rela-
a
(1998) 937e943.
tionships of a new model of arylpiperazines. 4. 1-[u-(4-arilpiperazin-1-yl)
[21] C. Hampel, P.C. Dolber, M.P. Smith, S.L. Savic, J.W. Thüroff, K.B. Thor,
D.A. Schwinn, Modulation of bladder alpha1-adrenergic receptor subtype
expression by bladder outlet obstruction, J. Urol. 167 (2002) 1513e1521.
alkyl]-3-diphenylmethylene-2,5-pyrrolidinediones and e3-(9H-fluoren-9-
ylidene)-2,5-pyrrolidinediones: study of the steric requirements of the
terminal amide fragment on 5-HT1A affinity/ selectivity, J. Med. Chem. 42
(1999) 36e49.
[22] C.G. Roehrborn, D.A. Schwinn, a1-Adrenergic receptors and their inhibitors in
lower urinary tract symptoms and benign prostatic hyperplasia, J. Urol. 171
(2004) 1029e1035.
[47] M.L. López-Rodríguez, M.L. Rosado, B. Benhamú, M.J. Morcillo, E. Fernández,
K.-J. Schaper, Synthesis and structure-activity relationships of a new model of
arylpiperazines. 2. Three-dimensional quantitative structure-activity rela-
tionships of hydantoin-phenylpiperazine derivatives with affinity for 5-HT1A
and a1 receptors. A comparison of CoMFA models, J. Med. Chem. 40 (1997)
1648e1656.
[48] D.J.J. Waugh, R.J. Gaivin, M.J. Zuscik, P. Gonzalez-Cabrera, S.A. Ross, J. Yun,
D.M. Perez, Phe-308 and Phe-312 in transmembrane domain 7 are major sites
of a1-adrenergic receptor antagonist binding, J. Biol. Chem. 276 (2001)
25366e25371.
[23] A.A. Hancock, S.A. Buckner, M.E. Brune, T.A. Esbenshade, L.M. Ireland,
S. Katwala, I. Milicic, M.D. Meyer, J.F. Kerwin Jr., M. Williams, Preclinical
pharmacology of fiduxosin, a novel alpha 1-adrenoceptor antagonist with
uroselective properties, J. Pharmacol. Exp. Ther. 300 (2002) 478e486.
[24] S. Kobayashi, Y. Tomiyama, S. Tatemichi, Y. Hoyano, M. Kobayashi,
Y. Yamazaki, Effects of silodosin and tamsulosin on the urethra and cardio-
vascular system in young and old dogs with benign prostatic hyperplasia, Eur.
J. Pharmacol. 613 (2009) 135e140.
[25] G. Sagratini, P. Angeli, M. Buccioni, U. Gulini, G. Marucci, C. Melchiorre,
E. Poggesi, D. Giardinà, Synthesis and a1-adrenoceptor antagonist activity of
tamsulosin analogs, Eur. J. Med. Chem. 45 (2010) 5800e5807.
[26] K. Nanda, K.S. Naruganahalli, S. Gupta, S. Malhotra, A. Tiwari, L.G. Hegde,
S. Jain, N. Sinha, J.B. Gupta, A. Chugh, N. Anand, A. Ray, RBx 6198: a novel
[49] G.-H. Kuo, C. Prouty, W.V. Murray, V. Pulito, L. Jolliffe, P. Cheung, S. Varga,
M. Evangelisto, J. Wang, Design, synthesis, and structure-activity relationships
of phthalimide-phenylpiperazines: a novel series of potent and selective a1a
adrenergic receptor antagonists, J. Med. Chem. 43 (2000) 2183e2195.
-
[50] F. Suzuki, S. Miyamoto, M. Takita, M. Oshita, Y. Watanabe, A. Kakizuka,
S. Narumiya, T. Taniguchi, I. Muramatsu, Cloning, functional expression and
tissue distribution of rabbit a1d-adrenoceptor, Biochim. Biophys. Acta 1323
(1997) 6e11.
[51] M. Satoh, K. Enamoto, H. Niwano, H. Fujimura, Y. Toyama, I. Takayanagi,
K. Koike, Regional differences in a1-adrenoceptor subtypes and mechanisms
in rabbit arteries, Eur. J. Pharmacol. 350 (1998) 67e73.
[52] M. Satoh, N. Nokubu, K. Matsuo, I. Takayanagi, 1A-Adrenoceptor subtype
effectively increases Ca2þ-sensitivity for contraction in rabbit thoracic aorta,
Gen. Pharmacol. 26 (1995) 357e362.
a
1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia,
Eur. J. Pharmacol. 607 (2009) 213e219.
[27] S. Li, G. Chiu, V.L. Pulito, J. Liu, P.J. Connolly, S.A. Middleton, Synthesis, in vitro
activities of (2-cyclopropoxyphenyl)piperidine derivatives for alpha 1a and
alpha 1d adrenergic receptor inhibitors, Med. Chem. 5 (2009) 15e22.
[28] E.J. Barreiro, C.A.M. Fraga, The utilization of the safrole, principal chemical
constituent of sassafras oil, in the synthesis of compounds actives in the
arachidonic acid cascade: antiinflammatory, analgesic and antithrombotic,
Quim. Nova 22 (1999) 744e759.
[29] H.J.C. Bezerra-Netto, D.I. Lacerda, A.L.P. Miranda, H.M. Alves, E.J. Barreiro,
C.A.M. Fraga, Design and synthesis of 3,4-methylenedioxy-6-nitrophe-
noxyacetylhydrazone derivatives obtained from natural safrole: new lead-agents
with analgesic and antipyretic properties, Bioorg. Med. Chem. 14 (2006)
7924e7935.
[30] T.N. Van, S. Debenedetti, N. De-Kimpe, Synthesis of coumarins by ring-
closing metathesis using Grubbs’ catalyst, Tetrahedron Lett. 44 (2003)
4199e4201.
[53] M.A. Scofield, F. Liu, P.W. Abel, W.B. Jeffries, Quantification of the steady state
expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse
transcription and a competitive polymerase chain reaction, J. Pharmacol. Exp.
Ther. 275 (1995) 1035e1042.
[54] P.H. Van der Graaf, N.P. Shankley, J.W. Black, Analysis of the activity of
1-adrenoceptor antagonists in rat aorta, Br. J. Pharmacol. 118 (1996) 299e310.
[55] W.A. Carroll, K.B. Sippy, T.A. Esbenshade, S.A. Buckner, A.A. Hancock,
M.D. Meyer, Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-
phenylthien, Bioorg. Med. Chem. Lett. 11 (2001) 1119e1121.
[31] C.A.M. Fraga, E.J. Barreiro, Design and synthesis of a new 4-oxa-8
u-11-deoxy-
5,6-dihydro prostacyclin analogue, Chem. Pharm. Bull. 44 (1996) 2157e2161.
[32] M.D. Meyer, A.A. Hancock, K. Tietje, K.B. Sippy, R. Prasad, D.M. Stout,
D.L. Arendsen, B.G. Donner, W.A. Carroll, Structure-activity studies for a novel
series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methyl-
amines possessing dual 5HT uptake inhibiting and a2-antagonistic activities,
J. Med. Chem. 40 (1997) 1050e1062.
[56] G.-H. Kuo, C. Prouty, W.V. Murray, V. Pulito, L. Jolliffe, P. Cheung, S. Varga,
M. Evangelisto, C. Shaw, Design, synthesis and biological evaluation of
pyridine-phenylpiperazines:
a novel series of potent and selective a1a-
adrenergic receptor antagonist, Bioorg. Med. Chem. 8 (2000) 2263e2275.
[57] S. Guimarães, D. Moura, Vascular adrenoceptors: an update, Pharmacol. Rev.
53 (2001) 319e356.
[33] C.M. Duarte, J.X. Araújo-Júnior, J.P. Parente, E.J. Barreiro, Síntese de novos
análogos de piperamidas hipotensoras, Rev. Bras. Farm 80 (1999) 35e38.
[34] C.M. Duarte, H. Verli, J.X. Araújo-Júnior, I.A. Medeiros, E.J. Barreiro,
C.A.M. Fraga, New optimized piperamide analogs with potent in vivo hypo-
tensive properties, Eur. J. Pharm. Sci. 23 (2004) 363e369.
[35] E.J. Barreiro, P.R.R. Costa, F.A.S. Coelho, F.M.C.J. Farias, Prostaglandin
analogues. Part 2. Synthesis of new derivatives fro safrole isolated from sas-
safraz oil, Chem. Res. (M) (1985) 2301e2332.
[58] L.A.S. Romeiro, C.A.M. Fraga, E.J. Barreiro, C.L.M. Silva, A.L.P. Miranda, E.V.
Tibiriçá, F.C.F. Brito, H.C.C.C. Almeida, F.G. Noel, Use of adrenergic N-phenyl-
piperazine antagonists, pharmaceutical compositions containing them, and
methods of preparing them, U.S. Patent Appl. (2007) 20070219213.
[59] C.L.M. Silva, F.G. Noel, E.J. Barreiro, Cyclic GMP-dependent vasodilatory
properties of LASSBio 294 in rat aorta, Br. J. Pharmacol. 135 (2002) 293e298.
[60] T. Kenakin, Drug Antagonism in Molecular Pharmacology: A Short Course.
Blackwell Science, Cambridge, 1996.